Gentex Corporation (GNTX)

UBS has maintained a Neutral rating and $25 price target for Gentex (NASDAQ:GNTX) ahead of the company's upcoming investor day, noting that the event is not expected to be a major near-term catalyst. The current price target is below InvestingPro's Fair Value, suggesting the stock may be undervalued. Despite recent mixed Q2 2026 results where Gentex surpassed earnings estimates but missed revenue expectations, the company improved net income and margins, leading Freedom Broker to downgrade its stock rating from buy to hold due to valuation concerns.

UBS maintained a Neutral rating and a $25 price target for Gentex Corp. (NASDAQ:GNTX) ahead of the company's upcoming investor day on August 27th. While UBS does not expect the event to be a major short-term catalyst, it could reinforce long-term growth opportunities. Gentex recently reported mixed Q2 2026 results, with adjusted earnings beating estimates but revenue falling short, leading Freedom Broker to downgrade the stock to hold.

Bank of America Corp DE increased its stake in Gentex Corporation (GNTX) by 43.3% in the first quarter, bringing its total holdings to 1.51 million shares valued at $32.93 million. Gentex reported Q1 EPS of $0.58, beating estimates, despite a 1% revenue decline. The company offers a 2.0% dividend yield, and analysts currently have a consensus "Hold" rating with an average price target of $26.80.

American Century Investment Management, Inc., American Century Companies, Inc., and the Stowers Institute for Medical Research have collectively reported a 5.2% beneficial ownership stake in Gentex Corporation (GNTX). This group owns 11,025,677 shares of Gentex common stock as of June 30, 2026, holding sole voting power over 10,863,349 shares and sole dispositive power over all 11,025,677 shares. The filing, a Schedule 13G, indicates that the shares were acquired for investment purposes in the ordinary course of business, not to influence control of the issuer.

Assenagon Asset Management S.A. recently acquired 134,967 shares of Gentex Corporation (NASDAQ:GNTX) valued at approximately $3.4 million, making them a new institutional holder. Despite Gentex exceeding quarterly earnings expectations with an EPS of $0.58, revenue saw a slight decline, and analyst sentiment remains cautious with an average "Hold" rating and a price target of $26.80. Insider activity also shows recent share sales by two directors.